Cartilage and chondrocyte pathology in the mucopolysaccharidoses: The role of glycosaminoglycan-mediated inflammation

Journal of Pediatric Rehabilitation Medicine

Volumn 3, Issue 2, 2010, Pages 85-88

  Simonaro, Calogera M ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

cartilage; inflammation; Mucopolysaccharidoses

Indexed keywords

GLYCOSAMINOGLYCAN; INFLIXIMAB; RECOMBINANT ENZYME;

APOPTOSIS; CARTILAGE CELL; CELL HYPERPLASIA; CLINICAL FEATURE; CONNECTIVE TISSUE; ENZYME REPLACEMENT; HUMAN; HURLER SYNDROME; IMMUNOPATHOLOGY; INFLAMMATION; MAROTEAUX LAMY SYNDROME; MOLECULAR BIOLOGY; MUCOPOLYSACCHARIDOSIS; NOTE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SYNOVIUM;

EID: 77954651674     PISSN: 18745393     EISSN: 18758894     Source Type: Journal    
DOI: 10.3233/PRM-2010-0120     Document Type: Note

References (23)

1. A. Alonso-Ruiz, J.I. Pijoan et al., Tumor necrosis factor a drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety, BMC Musculoskelet Disord 9 (2008), 52-63.
2. D. Auclair, L.K. Hein et al., Intra-articular enzyme administration for joint disease in feline mucopolysaccharidosis VI: enzyme dose and interval, Pediatr Res 59 (2006), 538-543.
3. J. Ausseil, N. Desmaris et al., Early neurodegeneration progresses independently of microglial activation by heparan sulfate in the brain of Mucopolysaccharidosis IIIB mice, PLoS ONE 3 (2008), e2296.
4. M.K. Boettger, S. Hensellek et al., Antinociceptive effects of tumor necrosis factor alpha neutralization in a rat model of antigen-induced arthritis: evidence of a neuronal, Arthritis Rheum 58 (2008), 2368-2378.
5. S.R. Goldring, Pathogenesis of bone erosions in rheumatoid arthritis, Curr Opin Rheumatol 4 (2002), 406-410.
6. B.A. Hemmings, Akt signaling: linking membrane events to life and death decisions, Science 275 (1997), 628-630.
7. X. Hu, J. Chen et al., Crosstalk among Jak-STAT, Toll-like receptor, and ITAM-dependent pathways in macrophage activation, Leukoc Biol 82 (2006), 237-243.
8. D. Laharie, E. Chanteloup et al., Tolerance and efficacy of a postponed retreatment with infliximab in Crohn's disease primary responders, Aliment Pharmacol Ther 29 (2009), 1240-1248.
9. J.A. Metcalf, Y. Zhang et al., Mechanism of shortened bones in mucopolysaccharidosis VII, Mol Genet Metab 97 (2009), 202-211.
10. K. Migita, K. Eguchi et al., TNF - a mediated expression of membrane-type matrix metalloproteinase in rheumatoid synovial fibroblasts, Immunol 89 (1996), 553-557.
11. E.F. Neufeld and J. Muenzer, The Metabolic and Molecular Bases of Inherited Disease, McGraw-Hill, New York, (2001), 3421-3452.
12. J.D. Nutall, L.K. Brumfield et al., Histomorphometric analysis of the tibial growth plate in a feline model of mucopolysaccharidosis type VI, Calcif Tissue Int 65 (1999), 47-52.
13. Y. Shigeyama, T. Pap et al., Expression of osteoclast differentiation factor in rheumatoid arthritis, Arthritis Rheum 43 (2000), 2523-2530.
14. C.M. Simonaro, M.E. Haskins et al., Articular chondrocytes from animals with a dermatan sulfate storage disease undergo a high rate of apoptosis and release nitric oxide and inflammatory cytokines: a possible mechanism underlying degenerative joint disease in the mucopolysaccharidoses, Lab Invest 81 (2001), 1319-1328.
15. C.M. Simonaro, M. D'Angelo et al., Joint and bone disease in mucopolysaccharidoses VI and VII: identification of new therapeutic targets and biomarkers using animal models, Pediatric Res 57 (2005), 701-707.
16. C.M. Simonaro, M. D'Angelo et al., Mechanism of glycosaminoglycan- mediated bone and joint disease: implications for the mucopolysaccharidoses and other connective tissue diseases, Am J Pathol 172 (2008), 112-122.
17. C.M. Simonaro, Y. Ge et al., Involvement of the Toll-like receptor 4 pathway and use of TNF-alpha antagonists for treatment of the mucopolysaccharidoses, Proc Natl Acad Sci U S A Dec 14 (2009). [Epub ahead of print].
18. V. Strand and J.A. Singh, Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials, Am J Manag Care 13 (2006), S237-S252.
19. K.R. Taylor, Y. Yamasaki et al., Recognition of hyaluronan released in sterile injury involves a unique receptor complex dependent on Toll-like receptor 4, CD44, and MD-2, J Biol Chem 282 (2007), 18265-18275.
20. M. Triantafilou and K. Triantafilou, Lipopolysaccaride recognition: CD14, TLRs and the LPS-activation cluster, Trends in Immuno 23 (2002), 301-304.
21. J.G. Walker, M.J. Ahern et al., Expression of Jak3, STAT1, STAT4, and STAT6 in inflammatory arthritis: unique Jak3 and STAT4 expression in dendritic cells in seropositive rheumatoid arthritis, Ann Rheum Dis 65 (2006), 149-156.
22. A.L. Weaver, Efficacy and safety of the anti-TNF biologic agents, Mod Rheumatol 14 (2004), 101-112.
23. R.O. Williams and M. Feldmann, Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis, Proc Natl Acad Sci USA 89 (1992), 9784-9788.